Navigation Links
USA's largest ever prostate cancer screening program shows high compliance and consistent results
Date:12/15/2008

Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the urology journal BJU International.

A total of 154,934 men and women aged from 55 to 74 took part in the multi-centre Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial and 38,349 men were selected at random to receive a prostate-specific antigen (PSA) test and a digital rectal examination (DRE).

"The aim of the study is to determine the impact of annual PSA and DRE screening on prostate cancer mortality by comparing the men who were screened with men undergoing standard medical care without screening" explains Professor Gerald Andriole, Chief of the Division of Urology at Washington University School of Medicine, USA.

"This paper reports the findings from the first three of the five annual follow-up screening rounds. It looks at whether the men continued to take part in the screening programme and examines the characteristics of the cancers that were discovered."

Ten screening centres took part in the research, which was funded by the National Cancer Institute.

Key test findings included:

  • The majority of the men included in the study complied with the PSA and DRE tests - 89% complied with both tests at baseline and this figure was 85% by year three.

  • Approximately one in seven men received either a positive PSA or DRE test at the baseline, one, two and three year screenings (14%, 13.5%, 14.4% and 15.1% respectively).

  • An average of 8% of the men had a PSA positive result of more than 4ng/mL over the four tests (7.9%, 7.7%, 8.2% and 8.8% respectively).

  • Just over 7% of the men had a positive DRE result when the four tests were averaged out (7.2%, 6.8%, 7.3% and 7.6% respectively).

  • Both tests were positive in just over 1% of cases (1.2%, 1%, 1.1% and 1.2% respectively).

Key cancer findings included:

  • 1,902 men (4.9%) were diagnosed with prostate cancer and just over 84% of these (1,603) were picked up as a result of PSA or DRE screening.

  • Just over a third of the cancers were picked up at baseline (34.2%). Cancers picked up at this stage tended to be more serious than cancers picked up later in the screening programme. For example, 5.8% of the cancers at baseline were stages three or four, compared with 1.5% in year three.

  • Cancers picked up at baseline were also more likely to have a higher Gleason score, meaning that the cancer was more aggressive and more likely to be fatal. 34% had a Gleason score of seven to ten at baseline, compared with an average of 25.6% in years one to three.

  • 84% of the men who were diagnosed as a result of PSA screening had a PSA of more than 4ng/mL.

  • But not all the cancer patients had an elevated PSA. DRE picked up a further 16% of cancer cases in patients who had a PSA of less than 4ng/mL.

  • The screening programme picked up 16 cancers per thousand men screened at baseline, 11.5 in year one, 10.8 in year two and 11.1 in year three.

"There has been much debate about the benefits of PSA screening in the United States" says Professor Andriole. "For example the American Cancer Society, the American Urological Association and the National Comprehensive Cancer Network recommend that normal risk men receive annual PSA screening with DRE from the age of 50.

"However, the US Preventative Services Task Force and the American College of Physicians - American Society of Internal Medicine do not recommend screening because they feel that clear benefits have not been demonstrated.

"Our research found that compliance was high with both PSA and DRE screening. It also showed that PSA and DRE screening consistently detected new cases of prostate cancer and that these became less and less aggressive as the screening programme progressed.

"Longer follow-up of this study group is necessary to link the test results to death rates and determine the benefits of PSA and DRE screening in reducing deaths due to prostate cancer."


'/>"/>

Contact: Annette Whibley
wizard.media@virgin.net
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Medscape Physician Connect Becomes Largest Online Physician Social Network with More than 100,000 Physicians
2. Dental Network of America Becomes Largest National Dental Network in the U.S.
3. Foundation Radiology Group Named One of 50 Largest Radiology Groups in the Country
4. Largest study of fertility patients shows concerns about embryo disposition
5. Courion Helps Reduce Costs at Nations Largest Operator of Senior Living Communities
6. Antibiotics Largest Cause of Drug-Induced Liver Damage
7. Kindred Healthcare, Nations Largest Post-Acute Healthcare Provider, Selects Allscripts Referral Management
8. Medical Technology to be Highlighted at World's Largest Simulation Exhibition
9. November 23 Marks Tenth Anniversary of the Largest Civil Settlement in U.S. History
10. Military, Industry Leaders to Speak at World's Largest Simulation Event
11. World's Largest Modeling and Simulation Exhibition Sells Out for '08
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... Switzerland (PRWEB) , ... March 27, 2017 , ... ... food industry. Conventional sodium testing methods are complicated and require expert user knowledge. ... a new analytical method dedicated to the simplified, yet highly accurate, determination of ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... GTEC Orange facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year ... be an opportunity for area-residents to celebrate two great years while also familiarizing ...
(Date:3/27/2017)... ... 2017 , ... Harris Communications, Inc., a leading provider of assistive technology ... the Deaf Seniors of America Conference, April 4-7 at the Hotel Westin Galleria in ... friendly staff from Harris Communications and to try out the newest assistive devices available ...
(Date:3/25/2017)... ... March 25, 2017 , ... Norland at Swissray is pleased to announce the ... subjects. The ELITE DXA has an active scan window, which is more than double ... fit in the scan area could not undergo an accurate total body bone density or ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 27, 2017  Sophiris Bio Inc. (NASDAQ: ... clinical late-stage biopharmaceutical company developing topsalysin (PRX302) for ... reported fourth quarter and full year 2016 financial ... Key Corporate Highlights: Advanced Topsalysin ... During 2016, the Company reported successful results with ...
(Date:3/27/2017)... , March 27, 2017 BioLineRx ... and immunology, announced today that AGI-134, an immunotherapy for the ... of Agalimmune Ltd., will be featured at the upcoming ... Washington, DC to be held on ... ...
(Date:3/27/2017)... , March 27, 2017 The staggering cost ... wealthiest countries have access to the latest treatment options ... the US, many patients have inadequate or no health ... skip therapy altogether. Access to modern cancer treatment is ... countries. The mission statements of pharmaceutical ...
Breaking Medicine Technology: